These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 12352398)

  • 1. Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
    Thalmann GN; Markwalder R; Walter B; Studer UE
    J Urol; 2002 Oct; 168(4 Pt 1):1381-5. PubMed ID: 12352398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
    Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
    Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Percutaneous Bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ].
    Yamashita S; Yogi Y; Taniguchi K; Morimitsu H; Suzu H; Kanetake H; Saito Y; Kubota S
    Hinyokika Kiyo; 1992 Oct; 38(10):1095-9. PubMed ID: 1481770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.
    Bree KK; Hensley PJ; Brooks NA; Matulay J; Li R; Nogueras Gonzalez GM; Navai N; Grossman HB; Matin SF; Dinney CPN; Kamat AM
    BJU Int; 2021 Nov; 128(5):568-574. PubMed ID: 33484074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
    Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
    Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncologic Outcomes Following Robot-Assisted Laparoscopic Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma.
    Aboumohamed AA; Krane LS; Hemal AK
    J Urol; 2015 Dec; 194(6):1561-6. PubMed ID: 26192256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
    Motamedinia P; Keheila M; Leavitt DA; Rastinehad AR; Okeke Z; Smith AD
    J Endourol; 2016 Mar; 30(3):262-7. PubMed ID: 26630130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological Behavior and Long-Term Outcomes of Carcinoma In Situ in Upper Urinary Tract Managed by Radical Nephroureterectomy.
    Inamoto T; Matsuyama H; Ibuki N; Komura K; Takahara K; Fujimoto K; Shiina H; Sakano S; Nagao K; Miyake M; Tatsumi Y; Yasumoto H; Azuma H;
    J Urol; 2018 Apr; 199(4):933-939. PubMed ID: 29037861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of intrarenal Bacillus Calmette-Guérin/interferon-α2B for biopsy-proven upper-tract carcinoma in situ.
    Shapiro EY; Lipsky MJ; Cha DY; McKiernan JM; Benson MC; Gupta M
    J Endourol; 2012 Dec; 26(12):1645-50. PubMed ID: 22834939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage topical therapy for upper tract urothelial carcinoma.
    Balasubramanian A; Metcalfe MJ; Wagenheim G; Xiao L; Papadopoulos J; Navai N; Davis JW; Karam JA; Kamat AM; Wood CG; Dinney CP; Matin SF
    World J Urol; 2018 Dec; 36(12):2027-2034. PubMed ID: 29804202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma.
    Rink M; Robinson BD; Green DA; Cha EK; Hansen J; Comploj E; Margulis V; Raman JD; Ng CK; Remzi M; Bensalah K; Kabbani W; Haitel A; Rioux-Leclercq N; Guo CC; Chun FK; Kikuchi E; Kassouf W; Sircar K; Sun M; Sonpavde G; Lotan Y; Pycha A; Karakiewicz PI; Scherr DS; Shariat SF
    J Urol; 2012 Aug; 188(2):398-404. PubMed ID: 22698626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Guérin therapy.
    Kojima Y; Tozawa K; Kawai N; Sasaki S; Hayashi Y; Kohri K
    Int J Urol; 2006 Apr; 13(4):340-4. PubMed ID: 16734847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Tolerability of Bacillus Calmette-Guérin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
    Tomisaki I; Kubo T; Minato A; Fujimoto N
    Cancer Invest; 2018 Feb; 36(2):152-157. PubMed ID: 29393701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
    Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK
    Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of bacillus Calmette-Guérin perfusion therapy for carcinoma in situ of the upper urinary tract.
    Miyake H; Eto H; Hara S; Okada H; Kamidono S; Hara I
    Int J Urol; 2002 Dec; 9(12):677-80. PubMed ID: 12492951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.